Flexion Therapeutics, Inc (FLXN)

Etorro trading 970x250
Flexion Therapeutics, Inc (FLXN) Logo

About Flexion Therapeutics, Inc

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Address: 10 Mall Road, Burlington, MA, United States, 01803

Flexion Therapeutics, Inc News and around…

Latest news about Flexion Therapeutics, Inc (FLXN) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
19 Nov, 2021 FinancialContent

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:EQT) from Equal-Weight to Overweight. For the ...

Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management
19 Nov, 2021 Yahoo! Finance

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (Nasdaq: FLXN). “This is an

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ECHO, ACBI, HRC, FLXN; Shareholders are Encouraged to Contact the Firm
04 Nov, 2021 FinancialContent
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
03 Nov, 2021 Yahoo! Finance

Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.

Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript
03 Nov, 2021 Yahoo! Finance

Joining me as speakers on today's call are Dave Stack, Chairman and Chief Executive Officer; and Charlie Reinhart, Chief Financial Officer. Before we begin, let me remind you that today's call will include forward-looking statements based on current expectations, including those related to the potential transaction between Pacira and Flexion Therapeutics.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACBI, GTS, ADTN, COLB, DSPG, FLXN; Shareholders are Encouraged to Contact the Firm
02 Nov, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
02 Nov, 2021 Yahoo! Finance

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, COLB, FTSI, FLXN; Shareholders are Encouraged to Contact the Firm
01 Nov, 2021 Yahoo! Finance

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Great Western Bancorp, Inc. (NYSE: GWB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to First Interstate BancSystem, Inc. Under the terms of the agreement, Great Western shareholders will receive 0.8425 shares of First Interstate Class A common stock for each Great Western

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN
30 Oct, 2021 Yahoo! Finance

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Flexion Therapeutics, Inc. ("FLXN" or the "Company") (FLXN) relating to its proposed acquisition by Pacira BioSciences, Inc. Under the terms of the agreement, FLXN shareholders will receive $8.50 in cash per share they own.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm
28 Oct, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to Decline
27 Oct, 2021 Yahoo! Finance

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations
27 Oct, 2021 Yahoo! Finance

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
25 Oct, 2021 Yahoo! Finance

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ESBK, FLXN, COLB, CXP; Shareholders are Encouraged to Contact the Firm
22 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Elmira Savings Bank (NASDAQ: ESBK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Community Bank System, Inc. for $23.10 per share in cash. If you are an Elmira shareholder, click here to learn more about your rights and options. Flexion Therapeutics, Inc. (NASDAQ: FLXN)

Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Meredith Corporation, Aspen Technology, Flexion, and Columbia Banking System on behalf of Stockholders and Encourages Investors to Contact the Firm
21 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Meredith Corporation (NYSE: MDP), Aspen Technology, Inc. (NASDAQ: AZPN) (“AspenTech”), Flexion Therapeutics, Inc. (NASDAQ: FLXN), and Columbia Banking System, Inc. (NASDAQ: COLB). Additional information about each potential action can be found at the link provided. Meredith Corporation (NYSE: MDP) Buyer: InterActiveCorp (NASDAQ: IAC

RYJ's Holdings Imply 25% Gain Potential
21 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $79.04 per unit.

Lifshitz Law Firm, P.C. Announces Investigation of ADMS, ACBI, FLXN, and HBMD
21 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ADMS to Supernus Pharmaceuticals, Inc. for $8.10 in cash per share of ADMS owned. If you are an investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FLXN, AZPN, COLB, LMRK; Shareholders are Encouraged to Contact the Firm
20 Oct, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
19 Oct, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / October 19, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. (NASDAQ:ADMS)Agreement Announcement: October 11, 2021 Transaction Details:Upon the closing of the transaction, Supernus will acquire Adamas through a tender offer for $8.

What 5 Analyst Ratings Have To Say About Flexion Therapeutics
19 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Flexion Therapeutics (NASDAQ:FLXN) within the last quarter: ...

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct, 2021 FinancialContent

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:INDP) from Hold to Buy. Indaptus Therapeutics ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, ACBI, SQ; Shareholders are Encouraged to Contact the Firm
15 Oct, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

First Week of December 17th Options Trading For Flexion Therapeutics (FLXN)
15 Oct, 2021 FinancialContent

Investors in Flexion Therapeutics, Inc. (FLXN) saw new options begin trading this week, for the December 17th expiration..

Moore Kuehn Encourages MDP, DUNE, FLXN, and AZPN Investors to Contact Law Firm
15 Oct, 2021 Yahoo! Finance

Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Analyst Ratings For Flexion Therapeutics
12 Oct, 2021 FinancialContent

Over the past 3 months, 4 analysts have published their opinion on Flexion Therapeutics (NASDAQ:FLXN) stock. These analysts are ...

FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN
12 Oct, 2021 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN) to Pacira BioSciences, Inc. (NasdaqGS: PCRX). Under the terms of the proposed transaction, shareholders of Flexion will receive only $8.50 in cash and one non-tradable contingent value right (CVR) worth up to $8.00 per share in cash (assuming certain conditions are met) for each share of Flexion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
12 Oct, 2021 FinancialContent

Upgrades For Callaway Golf Co (NYSE:ELY), Compass Point upgraded the previous rating of Neutral to Buy. Callaway Golf earned $0.36 in ...

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

10 Biggest Price Target Changes For Tuesday
12 Oct, 2021 FinancialContent

Evercore ISI Group raised Lear Corporation (NYSE: LEA) price target from $170 to $220. Lear shares fell 0.3% to close at ...

46 Biggest Movers From Yesterday
12 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full ...

Flexion Therapeutics, Inc (FLXN) is a NASDAQ Common Stock listed in , ,

970x250